Rivaroxaban and Aspirin in Patients With Symptomatic Artery Disease: A Subanalysis of the COMPASS Random

JAMA Cardiology

6, 21-29

DOI: 10.1001/jamacardio.2020.4390

Citation Report

#	Article	IF	Citations
1	The Efficacy and Safety of Direct Oral Anticoagulants Plus Aspirin in Symptomatic Lower Extremity Peripheral Arterial Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Thrombosis and Thrombolysis, 2021, 52, 904-913.	2.2	6
2	Safety and Efficacy of Vitamin K Antagonists Versus Rivaroxaban in Hemodialysis Patients With Atrial Fibrillation: A Multicenter Randomized Controlled Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 1474-1483.	7.1	184
3	Prevention and Management of Urgent/Emergent Limb Ischemia. Current Cardiology Reports, 2021, 23, 1-7.	4.5	2
4	Review New Concepts in Pharmacotherapy for Peripheral Arterial Disease. Current Opinion in Cardiology, 2021, 36, 720.	2.2	3
5	Advances in Revascularization for Peripheral Artery Disease: Revascularization in PAD. Circulation Research, 2021, 128, 1885-1912.	15.7	228
6	Contemporary Medical Management of Peripheral Artery Disease. Circulation Research, 2021, 128, 1868-1884.	15.7	153
7	Antithrombotic Therapy in Patients With Peripheral Artery Disease: A Focused Review on Oral Anticoagulation. International Journal of Molecular Sciences, 2021, 22, 7113.	5.9	17
8	Low-Dose Rivaroxaban and Aspirin Among Patients With Peripheral Artery Disease: A Meta-Analysis of the COMPASS and VOYAGER Trials. European Journal of Preventive Cardiology, 2022, 29, e181-e189.	6.1	38
9	Under-Prescription of Medical Treatment for Peripheral Artery Disease in the Under 50s: A Retrospective Study. Angiology, 2022, 73, 338-343.	2.4	6
10	Pharmacological Management of Obstructive Peripheral Arterial Disease: Two Case Reports. Hospital Practice (1995), 2021, 49, 379-383.	1.2	0
11	Editor's Choice – External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients With Symptomatic Lower Extremity Artery Disease in France: The COPART Registry. European Journal of Vascular and Endovascular Surgery, 2021, 62, 439-449.	3.2	33
12	Klinische Angiologie. Springer Reference Medizin, 2025, .	0.0	16
13	Principal Predictors of Major Adverse Limb Events in Diabetic Peripheral Artery Disease: A Narrative Review. Atherosclerosis Plus, 2021, 46, 1-14.	2.5	15
14	Applying Randomised Trials to the Real World: A VOYAGER of Discovery. European Journal of Vascular and Endovascular Surgery, 2022, 63, 295.	3.2	1
15	Update on the Pathophysiology and Medical Treatment of Peripheral Artery Disease. Nature Reviews Cardiology, 2022, 19, 456-474.	62.4	217
16	Antithrombotic Therapy in Peripheral Artery Disease: Risk Stratification and Clinical Decision Making. Canadian Journal of Cardiology, 2022, 38, 654-661.	3.8	7
17	Prevention of Arterial and Venous Thrombotic Events in Symptomatic Peripheral Arterial Disease Patients After Lower Extremity Revascularization in the VOYAGER PAD Trial: Dual Anticoagulant/Antiplatelet Regimen vs Antiplatelet Therapy Alone. Journal of Thrombosis and Haemostasis, 2022, 20, 1193-1205.	5.0	15
18	Direct Oral Anticoagulants and Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 553-564.	7.9	13

#	Article	IF	Citations
19	Global Death Burden and Attributable Risk Factors of Peripheral Artery Disease by Age, Sex, SDI Regions, and Countries From 1990 to 2030: Results From the Global Burden of Disease Study 2019. Atherosclerosis, 2022, 347, 17-27.	7.0	41
20	Patients Selected for Dual Pathway Inhibition in Clinical Practice Have Similar Characteristics and Outcomes to Those Included in the COMPASS Randomized Trial: The XATOA Registry. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 825-836.	5.0	29
21	Peripheral Arterial Disease (Pathophysiology, Presentation, Prevention/Management). , 2022, .		1
22	Direct Oral Anticoagulants and Peripheral Arterial Disease. Galenika Medical Journal, 2022, 1, 76-79.	0.1	0
23	Delivery of Rivaroxaban and Chitosan Rapamycin Microparticle With Dual Antithrombosis and Antiproliferation Functions Inhibits Venous Neointimal Hyperplasia. Drug Delivery, 2022, 29, 1994-2001.	8.3	7
24	Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy. Drugs, 2022, 82, 1165-1177.	15.5	14
25	Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies. Journal of the Society for Cardiovascular Angiography & Interventions, 2022, 1, 100513.	2.3	25
26	Antithrombotic Therapy Following Revascularization for Chronic Limb-Threatening Ischaemia: A European Survey From the ESC Working Group on Aorta and Peripheral Vascular Diseases. European Heart Journal - Cardiovascular Pharmacotherapy, 2023, 9, 201-207.	5.0	15
27	Anticoagulation and Antiplatelet Agents in Peripheral Arterial Interventions. Seminars in Interventional Radiology, 2022, 39, 364-372.	1.1	2
28	Characteristics, Antithrombotic Patterns, and Prognostic Outcomes in Claudication and Critical Limb-Threatening Ischemia Undergoing Endovascular Therapy. Journal of Endovascular Therapy, 2024, 31, 622-633.	2.1	8
29	Direct Oral Anticoagulants as the First Choice of Anticoagulation for Patients With Peripheral Artery Disease to Prevent Adverse Vascular Events: A Systematic Review and Meta-Analysis. Journal of Cardiovascular Development and Disease, 2023, 10, 65.	2.9	14
30	Evidenzbasierte antithrombotische Therapie der peripheren arteriellen Verschlusskrankheit (PAVK). Gefasschirurgie, 2023, 28, 208-215.	0.4	2
31	Diabetic Vascular Diseases: Molecular Mechanisms and Therapeutic Strategies. Signal Transduction and Targeted Therapy, 2023, 8, 1-29.	69.0	712
32	Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions. Journal of Cardiovascular Development and Disease, 2023, 10, 164.	2.9	21
33	Low Dose Rivaroxaban for the Management of Atherosclerotic Cardiovascular Disease. Journal of Thrombosis and Thrombolysis, 2023, 56, 91-102.	2.2	9
34	Micro- and Macrovascular Effects of Inflammation in Peripheral Artery Disease—Pathophysiology and Translational Therapeutic Approaches. Biomedicines, 2023, 11, 2284.	4.9	22
35	Limb Preservation for the Vascular Specialist. , 2023, .		2
36	The Cellular and Protein Arms of Coagulation in Diabetes: Established and Potential Targets for the Reduction of Thrombotic Risk. International Journal of Molecular Sciences, 2023, 24, 15328.	5.9	18

#	Article	IF	Citations
37	Current Medical Therapy and Revascularization in Peripheral Artery Disease of the Lower Limbs: Impacts on Subclinical Chronic Inflammation. International Journal of Molecular Sciences, 2023, 24, 16099.	5.9	9
38	Comparison of Rivaroxaban-Based Dual Antithrombotic and Antiplatelet Therapies for Symptomatic Patients With Lower-Extremity Peripheral Artery Disease Post-Revascularization: A Retrospective Cohort Study. Therapeutic Advances in Chronic Disease, 2023, 14, 20406223231213262.	3.1	1
39	Intravascular Ultrasound Use in Peripheral Arterial and Deep Venous Interventions: Multidisciplinary Expert Opinion From SCAI/AVF/AVLS/SIR/SVM/SVS. Journal of Vascular and Interventional Radiology, 2024, 35, 335-348.	2.2	24
40	Intravascular Ultrasound Use in Peripheral Arterial and Deep Venous Interventions: Multidisciplinary Expert Opinion From SCAI/AVF/AVLS/SIR/SVM/SVS. Journal of the Society for Cardiovascular Angiography & Interventions, 2024, 3, 101205.	2.3	19
41	The Paradox of Direct-Acting Anticoagulants in Peripheral Arterial Disease in Spain. Angiologia, 2024, .	0.1	0
42	Nationwide Study in France to Predict One-Year Major Bleeding and Validate the OAC3-PAD Score in Patients Undergoing Revascularisation for Lower Extremity Arterial Disease. Angiologia, 2024, .	0.1	0
43	Medical Therapy for Peripheral Artery Disease. Current Cardiology Reports, 2024, 26, 651-659.	4.5	13
44	Polyvascular Disease: A Narrative Review of Risk Factors, Clinical Outcomes and Treatment. Current Cardiology Reports, 2024, 26, 505-520.	4.5	15
45	New Horizons in Peripheral Artery Disease. Age and Ageing, 2024, .	6.9	43
46	Challenges and Opportunities in the Management of Type 2 Diabetes in Patients With Lower Extremity Peripheral Artery Disease: A Tailored Diagnosis and Treatment Review. Cardiovascular Diabetology, 2024, 23, 1-16.	15.7	29
47	Epidemiology and Burden of Peripheral Artery Disease in People With Type 2 Diabetes: A Systematic Literature Review. Diabetes Therapy, 2024, 15, 1893-1961.	4.4	44
48	Early Thrombus Formation Is Required for Eccentric and Heterogeneous Neointimal Hyperplasia Under Disturbed Flow. Journal of Thrombosis and Haemostasis, 2024, 22, 3614-3628.	5.0	9
49	2024 ESC Guidelines for the Management of Peripheral Arterial and Aortic Diseases: Developed by the Task Force on the Management of Peripheral Arterial and Aortic Diseases of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), and the European Society of Vascular Medicine (ESVM). European Heart Journal, 2024, 45, 3538-3700.	14.7	1,197
50	Prevent III Score as a Predictor of Limb Salvage and Mortality After Aortoiliac Revascularization. Turkish Journal of Thoracic and Cardiovascular Surgery, 2024, 32, 253-260.	0.5	0
51	Rivaroxaban Plus Aspirin After Lower–Extremity Revascularization. Expert Review of Hematology, 2024, 17, 877-884.	2.7	1
52	Was ist neu im Management der peripheren arteriellen Verschlusskrankheit und der aortalen Erkrankungen?. Herz, 2025, 50, 25-33.	1.8	0
53	Dual Pathway Inhibition in Patients With Peripheral Artery Disease in Germany. Vasa - European Journal of Vascular Medicine, 2025, 54, 142-149.	2.7	1
54	Femoropopliteal Interventions for Peripheral Artery Disease: A Review of Current Evidence and Future Directions. Interventional Cardiology Clinics, 2025, 14, 243-256.	1.1	3

#	Article	IF	Citations
55	Rivaroxaban to Reduce the Risk of Major Cardiovascular Events in Patients With Chronic Coronary Artery Disease or Peripheral Artery Disease: A Narrative Review. Expert Opinion on Drug Safety, 2025, 24, 261-271.	3.2	7
56	Dual Pathway Inhibition in Patients With Coronary Artery Disease (CAD) in Clinical Practice in Germany: Results From the German CAD Subgroup of the XATOA Registry. Clinical Research in Cardiology, 2025, .	3.9	0
57	TwPAD Registry: A Prospective, Multicenter Registry of Chronic Peripheral Arterial Disease Involving Lower Limbs in Taiwan. Journal of the Chinese Medical Association, 2025, 88, 389.	2.2	0
58	Short-Term Effects of Rivaroxaban Combined With Aspirin in the Treatment of Lower Limb Arterial Atherosclerosis Occlusion With Stent Placement: A Retrospective Study. Medicine (United States), 2025, 104, e42147.	2.1	0
59	Intravascular Imaging for Peripheral Artery Disease and Endovascular Intervention of the Lower Extremities. Current Cardiovascular Imaging Reports, 2025, 18, 6.	0.7	3
60	Aspirin Plus Rivaroxaban vs Aspirin Alone: Improvement of Claudication, Limb Pain and Ankle-Brachial Index in Diabetic Peripheral Arterial Disease (PAD) Before Revascularization: A Clinical Randomized Trial. International Cardiovascular Research Journal, 2025, 19, e154736.	0.4	1
61	Oral Anticoagulant Management for Peripheral Vascular Disease. Advances in Surgery, 2025, 59, 161-199.	2.1	0
62	Systematic Review of the Use of Oral Anticoagulants in Patients With Peripheral Arterial Disease. Future Cardiology, 2025, 21, 711-723.	1.2	2
63	Selecting Oral Antithrombotic Therapies in Peripheral Arterial Disease: A Guide for Practitioners. American Journal of Health-System Pharmacy, 2025, 82, e868-e877.	1.4	1
64	Dual Pathway Inhibition Versus Antiplatelet Therapy for "Symptomatic" Lower-Extremities Peripheral Artery Disease in Diabetes Mellitus: A Systematic Review and a Meta-Analysis of Randomized Controlled Trials for the Development of the Italian Guidelines for the Treatment of Diabetic Foot Syndrome. Acta Diabetologica, 2026, 63, 1-13.	3.8	0
65	Coronary Artery Disease and Atherosclerosis in Other Vascular Districts: Epidemiology, Risk Factors and Atherosclerotic Plaque Features. Life, 2025, 15, 1226.	4.3	16
66	Unveiling Biomarkers via Plasma Metabolome Profiling for Diabetic Macrovascular and Microvascular Complications. Cardiovascular Diabetology, 2025, 24, 1-14.	15.7	12
67	Research Progress on Acupoint Catgut Embedding as an Adjunctive Therapy for Arteriosclerosis Obliterans of the Lower Extremities of Cold Coagulation and Blood Stasis. Advances in Clinical Medicine, 2025, 15, 1593-1597.	0.1	0
68	Klinische Angiologie. Springer Reference Medizin, 2025, .	0.0	0
69	Optimizing Selection of P2Y12 Inhibiting Therapy: Clopidogrel, Prasugrel or Ticagrelor. Expert Opinion on Pharmacotherapy, 2025, 26, 1565-1581.	3.5	3
70	Dual Versus Single Antiplatelet Therapy After Lower Extremity Revascularization in Peripheral Artery Disease: A Systematic Review and Meta-Analysis. World Journal of Cardiology, 2025, 17, 111941.	2.5	2
71	Risk Factors for Claudication and Management to Modify Them. , 2025, .		0
72	Practical Guidelines for the Prevention and Management of Diabetic Foot Disease in China. Burns and Trauma, 2025, 13, tkaf064.	10.2	10

#	Article	IF	Citations
73	Aspirin or P2Y12 Inhibitor Monotherapy in Atherosclerotic Cardiovascular Disease?. European Heart Journal, 2026, 47, 558-573.	14.7	22
74	Integrative Multi-Omics and Machine Learning Reveal Shared Biomarkers in Type 2 Diabetes and Atherosclerosis. International Journal of Molecular Sciences, 2026, 27, 136.	5.9	4
75	An Integrative Review of the Cardiovascular Disease Spectrum: Integrating Multi-Omics and Artificial Intelligence for Precision Cardiology. Diseases (Basel, Switzerland), 2026, 14, 31.	4.3	17
76	Net Clinical Benefit of Extended Dual Pathway Inhibition in Chronic Coronary Syndrome as Classified by the 2024 ESC Criteria: A COMPASS Substudy. European Heart Journal - Cardiovascular Pharmacotherapy, 2026, 12, 167-175.	5.0	2
77	Semaglutide in Peripheral Artery Disease and Diabetes by Baseline Disease Severity and Age: The STRIDE Trial. European Heart Journal, 2026, 47, 3301-3304.	14.7	2
78	Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial. Circulation: Cardiovascular Interventions, 2026, 19, e015229.	6.2	1
79	Follow-Up and Pharmacological and Non-Pharmacological Important Decisions in Patients After Bypass Surgery. , 2026, .		0
80	Anticoagulation in Peripheral Artery Disease: Scoping Review With ❄SAIMSARA. , 2026, .		0
81	Development and Validation of Risk Scores in Vascular Diseases. , 0, .		0
82	Efficacy and Safety of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Peripheral Arterial Disease: A Systematic Review and Meta-Analysis. Annals of Medicine and Surgery, 2026, 88, 4437-4447.	1.7	0
83	Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association. Circulation, 2026, 154, e188-e205.	24.6	2
84	Home-Based Intravenous Iloprost by Portable Elastomeric Pump in Chronic Limb-Threatening Ischemia: A Pilot Study. Vascular Medicine, 2026, 31, 526-534.	2.3	0
85	Antithrombotic Therapy for Lower Extremity Artery Diseases: A Literature Review. Непрерывное медицинское образование и наука, 2026, 21, 3-8.	0.0	0
86	Peripheral Artery Disease: Advances in Medical Therapy. European Heart Journal, 2026, .	14.7	2
87	Current Updates in Chronic Limb-Threatening Ischemia and Peripheral Arterial Disease Management. International Journal of Lower Extremity Wounds, 2026, .	2.0	1
88	Medical Management of Vascular Disease—Including Pharmacology of Drugs Used in Vascular Disease Management. , 2027, .		0
89	Polyvascular Atherosclerotic Disease Across Contemporary ESC Guidelines: Key Updates, Clinical Gaps, and Future Perspectives. Medicina (Lithuania), 2026, 62, 2047.	3.3	0